Inhibrx reports interim phase 2 data for cancer drug trial

Inhibrx Biosciences reported interim phase 2 data for INBRX-106 plus pembrolizumab showing a 44.0% confirmed objective response rate (11/25) versus 21.4% for pembrolizumab alone (6/28), including 3 complete responses in the combination arm and none in control. The stock rose nearly 8% on the update, and Stifel reiterated a Buy rating with a $300 price target versus a $134.35 share price. The company plans to start the phase 3 HexAgon portion in Q3 2026, with PFS data expected in Q4 2026.

Analysis

INBX is now trading like a de-risked platform story, but the market is still underpricing the asymmetry between interim signal quality and full readout risk. The key second-order effect is that strong immune activation without a large safety penalty materially improves the odds of combination adoption in first-line oncology, where payers and physicians tolerate less toxicity than in refractory settings. If the phase 3 launches on schedule, the stock can stay momentum-driven for months, but the next leg depends on whether the response delta translates into progression-free survival, not just early tumor shrinkage.

The competitive read-through is broader than INBX: any OX40/costimulation competitor now faces a much higher efficacy bar, and the bar is especially unforgiving because pembrolizumab backbones are already entrenched. That said, the market may be extrapolating too aggressively from an interim response rate in a small, enriched cohort; the main fragility is that immune-oncology programs often compress on duration-of-response and PFS even after promising ORR. A clean safety profile helps, but if PFS disappoints in Q4, the “platform premium” can unwind fast.

For MRK, the near-term impact is mostly strategic rather than financial: if INBX’s mechanism proves durable, it slightly raises the value of owning or partnering immune-combo assets to defend the Keytruda franchise. Conversely, a positive INBX readout increases pressure on incumbents to secure next-gen immuno-oncology optionality before data risk is fully resolved. The contrarian view is that the current move may already discount a best-case commercial outcome while ignoring dilution, trial execution, and the probability that the biology is real but not differentiated enough to justify current valuation multiples.

Key Decisions for Investors

• Trade INBX tactically long into the Q3 2026 phase 3 initiation catalyst, but size it as a momentum/event-driven position only; use a trailing stop if the stock loses post-data support, because the setup is vulnerable to a PFS miss in Q4 2026.
• Consider buying INBX call spreads on pullbacks rather than outright shares: the skew favors upside into trial commencement, but the binary readout risk argues for defined downside.
• Pair trade idea: long INBX / short a basket of lower-conviction immuno-oncology developers with similar costimulatory narratives, to isolate the read-through from broader biotech beta.
• For MRK, monitor as a strategic hedge rather than a pure earnings trade; if INBX data remains strong into late 2026, a small long MRK position can offset franchise-defense risk from next-gen combo competition.
• If INBX continues to gap higher on headlines without PFS confirmation, trim into strength above consensus-target extensions; the risk/reward becomes less attractive once the stock prices in a near-certain phase 3 success path.